



- (51) **International Patent Classification:**
A61K 9/20 (2006.01) *A61P 43/00* (2006.01)
- (21) **International Application Number:**
PCT/GB2023/051120
- (22) **International Filing Date:**
27 April 2023 (27.04.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/335,387 27 April 2022 (27.04.2022) US
- (71) **Applicant:** **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Porton Science Park, Bybrook Road, Porton Down, Salisbury, Wiltshire SP4 0BF (GB).
- (72) **Inventors:** **COOPER, John Alexander**; c/o KALVISTA PHARMACEUTICALS LIMITED, Porton Science Park, Bybrook Road, Porton Down, Salisbury, Wiltshire SP4 0BF (GB). **CROADSHAW, Oliver William**; c/o KALVISTA

PHARMACEUTICALS LIMITED, Porton Science Park, Bybrook Road, Porton Down, Salisbury, Wiltshire SP4 0BF (GB). **IVERSON, Matthew Scott**; 1499 Tallowood Circle, Cottonwood Heights, Utah 84093 (US). **SCHIANO, Serena**; c/o KALVISTA PHARMACEUTICALS LIMITED, Porton Science Park, Bybrook Road, Porton Down, Salisbury, Wiltshire SP4 0BF (GB). **SMITH, Michael David**; 2377 E Stringham Avenue, Salt Lake City, Utah 84109 (US).


- (74) **Agent:** **HOGGETT, Christopher James** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

- (54) **Title:** FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR

FIG. 2

ODT vs Film-Coated



- (57) **Abstract:** The present invention provides pharmaceutical dosage forms in the form of an orodispersible tablet comprising a plasma kallikrein inhibitor, mixtures for use in manufacturing processes for producing the orodispersible tablets of the invention and the uses of such orodispersible tablets. The orodispersible tablets of the present invention are particularly suitable for patients who may struggle to swallow tablets. The present invention provides on-demand treatments of bradykinin-mediated angioedema by orally administering a plasma kallikrein inhibitor to a patient in need thereof in the form of an orodispersible tablet.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))